Hims & Hers Health ($HIMS) stock declined 2% on Monday after rival GoodRx Holdings ($GDRX) announced a deal with Novo Nordisk ...

Hims & Hers first told investors about a regulatory review in July 2024, but Bloomberg's report adds new color on what ...

Investors who lost money in Hims & Hers (NYSE: HIMS) are being urged to actively participate in a securities class action lawsuit.

Hims & Hers shares fall after a report says the FTC has investigated its cancellation policies and billing practices for over ...

Meta (META) stock is dipping on reports that the company is restructuring its artificial intelligence (AI) unit for the ...

What To Know: Under the agreement, all strengths of the medications will now be available to eligible self-paying patients at $499 per month through GoodRx's platform.

Hims & Hers has been an incredible stock to own over the last few years, making shareholders rich. It has $2 billion in ...

GoodRx will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss medications.

Hims & Hers saw 73% revenue growth, driven by subscriber gains and ARPU hikes. Read here for an in-depth investment analysis ...

Hims & Hers continues to spend heavily on marketing to attract new customers. During the quarter, its marketing spending ...

Hims & Hers Health showed a sharper-than-expected revenue hiccup in Q2, sending the stock down. Click here to find out why ...

Shares of Hims & Hers Inc. fell after hours on Monday after the wellness and telehealth platform’s third-quarter forecast ...